Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 3rd Preview)
-
In-vivo CAR-T data boosts Legend Biotech momentum
Legend Biotech disclosed early clinical data for an in vivo CAR-T approach in non-Hodgkin’s lymphoma, reporting that the therapy reduced or eliminated signs of disease in all treated recipients. The company’s update is drawing attention as it attempts to position an in-vivo platform as a potential alternative to ex vivo manufacturing models such as Novartis’ Kymriah. The early results were highlighted alongside a sharp market reaction, underscoring investor appetite for next-generation CAR-T approaches that could simplify supply chains and shorten time to treatment. The response signals—though preliminary—also intensify competition around “in vivo” designs that aim to generate CAR-T activity directly inside the patient. For teams tracking CAR-T innovation, the key near-term question is whether the early all-responders profile holds as enrollment expands and whether safety, persistence, and durability remain consistent with the initial readout.
-
FDA scrutiny derails Fulcrum’s sickle cell PRC2 inhibitor program
Fulcrum Therapeutics is scrapping development of its lead sickle cell disease candidate, pociredir, and will pursue a strategic review after the FDA raised heightened concerns about risks and benefits. The agency’s position follows emerging safety signals associated with another PRC2 inhibitor class member, Ipsen’s Tazverik (tazemetostat), which was withdrawn from the U.S. market over secondary blood cancer concerns. Fulcrum said it had presented mechanistic and clinical rationale to the FDA based on target differences within PRC2 subunits and said no new severe safety signals were observed to date in pociredir, but the FDA ultimately determined malignancy risk is comparable across PRC2 complex interventions. The company disclosed it had received the official meeting record and that it sees no viable regulatory path forward. Shares moved sharply on the news, reflecting the severity of the FDA’s intervention and the difficulty of restarting programs in the PRC2 space without a clear pathway to mitigate the perceived malignancy hazard.
-
Lilly and Ascidian strike up-to-$1.9B RNA exon editing deal
Eli Lilly entered a global research and licensing collaboration with Ascidian Therapeutics worth up to $1.9 billion to pursue RNA exon editor therapies for inherited kidney diseases. Ascidian’s technology uses RNA exon editing—via engineered enzymes and cellular splicing machinery—to replace faulty exon segments at the RNA level without permanent DNA alteration. Under the agreement, Ascidian will lead discovery and early preclinical activities, while Lilly will handle later-stage preclinical development, clinical trials, manufacturing, and commercialization. The initial focus is on undisclosed monogenic kidney targets, with Lilly retaining exclusive rights for those agreed targets and an option to add additional ones. The deal adds another platform-driven bet to Lilly’s genetic medicines pipeline and positions RNA editing as an approach intended to expand delivery options beyond permanent genome editing and some constraints of DNA-targeted systems.
-
Phase 3 daraxonrasib doubles survival in advanced pancreatic cancer
Revolution Medicines’ daraxonrasib produced a major survival improvement in a Phase 3 trial of advanced pancreatic cancer, with median overall survival increasing to 13.2 months versus 6.7 months for chemotherapy. The RAS pathway inhibitor blocks all three RAS family members, aiming to overcome the limitations of prior single-mutant or single-RAS approaches. The Phase 3 RASolute 302 trial enrolled 500 participants, with efficacy consistent across the overall population and a common RAS-mutation subset. Investigators also reported disease progression slowing, with time to disease worsening extending in the daraxonrasib arm compared with standard-of-care treatment. The readout, presented at the American Society of Clinical Oncology annual meeting and published in The New England Journal of Medicine, is being framed by experts as a potential practice-changing shift after years of limited progress for pancreatic cancer patients.
-
Regulatory guidance clarifies how cell and gene therapy sponsors can reuse prior knowledge
The FDA’s Center for Biologics Evaluation and Research (CBER) published draft guidance describing how cell and gene therapy developers can leverage prior knowledge across clinical, nonclinical, and manufacturing work. The draft is designed to help sponsors document what is already known—publicly available or platform-derived—to reduce redundant study generation. The agency’s emphasis is on establishing a structured basis for using existing evidence when planning new programs, potentially affecting everything from study design justifications to manufacturing risk assessments. For developers, it can translate into clearer expectations for what counts as relevant prior knowledge and how it should be reflected in dossiers. The guidance arrives as the field continues to push for faster development cycles while maintaining safety and manufacturing quality for complex modalities, including AAV- and other vector-based therapies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.